Cytokinetics, Incorporated (CYTK) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $78.05: Quality below floor (3.1 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.0/10. Specifically: High short interest: 21%; Elevated put/call ratio: 1.83; Below-average business quality.
Cytokinetics is a fully-integrated specialty biopharmaceutical company that discovered and commercialized MYQORZO (aficamten), an oral cardiac myosin inhibitor approved in the U.S., EU, and China for symptomatic oHCM in December 2025. Commercial sales commenced in the U.S. in Q1... Read more
Sell if holding. Engine safety override at $78.05: Quality below floor (3.1 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.0/10. Specifically: High short interest: 21%; Elevated put/call ratio: 1.83; Below-average business quality. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 5.0/10, moderate confidence.
Passes 7/9 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, earnings proximity 78d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: moderate.
Recent Developments — Cytokinetics, Incorporated
Latest news
- Citigroup Initiates Coverage On Cytokinetics with Buy Rating, Announces Price Target of $99 — benzinga May 19, 2026 positive
- JP Morgan Maintains Overweight on Cytokinetics, Raises Price Target to $97 — benzinga May 12, 2026 positive
- Cytokinetics Presents New Data From Its SEQUOIA-HCM Pivotal Phase 3 Clinical Study Of Aficamten In Participants With oHC — benzinga May 11, 2026 positive
- HC Wainwright & Co. Maintains Buy on Cytokinetics, Raises Price Target to $140 — benzinga May 11, 2026 positive
- Wells Fargo Maintains Overweight on Cytokinetics, Raises Price Target to $105 — benzinga May 7, 2026 positive
Generated 2026-05-20T21:06:21Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHSuppliersingle source CMOs for MYQORZO10-K Item 1A: 'We currently rely on single source CMOs for the manufacture of any or all of MYQORZO as a finished drug product and the active pharmaceutical ingredient and registered starting materials used in the production of MYQORZO'
- MEDIUMcounterpartySanofi10-K Item 1: 'We depend on Sanofi for commercialization of MYQORZO in China'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
1 floor-breaker
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $78.05: Quality below floor (3.1 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.0/10. Specifically: High short interest: 21%; Elevated put/call ratio: 1.83; Below-average business quality. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $72.44. Score 5.0/10, moderate confidence.
Take-profit target: $94.23 (+21.0% upside). Prior stop was $72.44. Stop-loss: $72.44.
Concentration risk — Supplier: single source CMOs for MYQORZO; Quality below floor (3.1 < 4.0).
Cytokinetics, Incorporated trades at a P/E of N/A (forward -16.1). TrendMatrix value score: 7.5/10. Verdict: Sell.
27 analysts cover CYTK with a consensus score of 4.0/5. Average price target: $105.
What does Cytokinetics, Incorporated do?Cytokinetics is a fully-integrated specialty biopharmaceutical company that discovered and commercialized MYQORZO...
Cytokinetics is a fully-integrated specialty biopharmaceutical company that discovered and commercialized MYQORZO (aficamten), an oral cardiac myosin inhibitor approved in the U.S., EU, and China for symptomatic oHCM in December 2025. Commercial sales commenced in the U.S. in Q1 2026; Sanofi commercializes MYQORZO in China and Bayer has exclusive rights in Japan.